Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 7/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12255070 | 1.00 | CYP3A4 (0.49) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL2070165 | 1.00 | CYP3A4 (0.49) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL14076891 | 1.00 | CYP3A4 (0.49) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL133493 | 1.00 | CYP3A4 (0.49) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL14076892 | 0.91 | MEN1 (0.48) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL12749671 | 0.91 | MEN1 (0.48) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL2069633 | 0.91 | CYP3A4 (0.50) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL2069344 | 0.91 | CYP3A4 (0.50) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL14198745 | 0.91 | CYP3A4 (0.50) | CYP3A4MAOAMAOBESR1ESR2 | |
| SCHEMBL678187 | 0.91 | CYP3A4 (0.50) | CYP3A4MAOAMAOBESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330059-A1 | 3-PHENYL-2H-CHROMENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S, CONTAINING SAME | NEUROBIONET, INC. (KR) | 2023-10-19 | — | — | US | disclosed |
| US-11559510-B2 | Isoflavonoid composition with improved pharmacokinetics | NOXOPHARM LIMITED (AU) | 2023-01-24 | — | — | US | disclosed |
| WO-2022071670-A1 | 3-PHENYL-2H-CHROMENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S, CONTAINING SAME | 주식회사 뉴로바이오넷 | 2022-04-07 | — | — | WO | disclosed |
| US-11229703-B2 | Radiotherapy improvements | NOXOPHARM LIMITED (AU) | 2022-01-25 | — | — | US | disclosed |
| EP-3939583-A1 | IMPROVEMENTS IN CANCER TREATMENT WITH ISOFLAVONOIDS | Noxopharm Limited (AU) | 2022-01-19 | — | — | EP | disclosed |
| US-20210338576-A1 | CANCER TREATMENT | NOXOPHARM LIMITED (AU) | 2021-11-04 | — | — | US | disclosed |
| US-20210275493-A1 | IMMUNO-ONCOLOGY THERAPY USING ISOFLAVONE COMPOUNDS | NOXOPHARM LIMITED (AU) | 2021-09-09 | — | — | US | disclosed |
| EP-3191464-B1 | SYNTHESIS OF ISOFLAVANES AND INTERMEDIATES THEREOF | SYSTEM BIOLOGIE AG (CH) | 2019-11-06 | — | — | EP | disclosed |
| US-20190282540-A1 | TARGETED DRUG DELIVERY | NOXOPHARM LIMITED (AU) | 2019-09-19 | — | — | US | disclosed |
| US-20190262451-A1 | RADIOTHERAPY IMPROVEMENTS | NOXOPHARM LIMITED (AU) | 2019-08-29 | — | — | US | disclosed |
| EP-1861090-A1 | ANTI-INFLAMMATORY MODALITIES | Novogen Research Pty. Ltd. (AU) | 2007-12-05 | — | — | EP | disclosed |
| US-7202273-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2007-04-10 | — | — | US | disclosed |
| US-7202273-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2007-04-10 | — | — | US | disclosed |
| WO-2006108212-A1 | ANTI-INFLAMMATORY MODALITIES | NOVOGEN RESEARCH PTY LTD (AU) | 2006-10-19 | — | — | WO | disclosed |
| US-20060217564-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2006-09-28 | — | — | US | disclosed |
| WO-2005103025-A1 | ISOFLAVENE SYNTHETIC METHOD AND CATALYST | NOVOGEN RESEARCH PTY LTD (AU) | 2005-11-03 | — | — | WO | disclosed |
| US-20050143588-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2005-06-30 | — | — | US | disclosed |
| EP-1153020-A4 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RES PTY LTD (AU) | 2002-08-21 | — | — | EP | disclosed |
| EP-1153020-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | Novogen Research Pty. Ltd. (AU) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049009-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RESEARCH PTY. LTD. (AU) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282540-A1 | TARGETED DRUG DELIVERY | NTRK1, SI, TIE1 | CYP3A4 741/4885MAOA 1807/4885MAOB 1478/4885 |
| US-20060217564-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | CYP3A4 14/4885MAOA 1190/4885MAOB 1006/4885 |
| US-11559510-B2 | Isoflavonoid composition with improved pharmacokinetics | SI, CYP51A1, CYP19A1 | CYP3A4 90/4885MAOA 1810/4885MAOB 905/4885 |
| US-20230330059-A1 | 3-PHENYL-2H-CHROMENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S, CONTAINING SAME | APP, BACE1, MAPT | CYP3A4 632/4885MAOA 492/4885MAOB 1168/4885 |
| US-20210275493-A1 | IMMUNO-ONCOLOGY THERAPY USING ISOFLAVONE COMPOUNDS | IKZF1, IFNG, IL2 | CYP3A4 1453/4885MAOA 4292/4885MAOB 3457/4885 |
| US-20190262451-A1 | RADIOTHERAPY IMPROVEMENTS | MRE11, TP53, CHEK2 | CYP3A4 3423/4885MAOA 4377/4885MAOB 4315/4885 |
| US-20050143588-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | CYP3A4 14/4885MAOA 1190/4885MAOB 1006/4885 |
| US-20210338576-A1 | CANCER TREATMENT | TP53, HIF1AN, HIF1A | CYP3A4 1459/4885MAOA 3896/4885MAOB 3431/4885 |
| US-11229703-B2 | Radiotherapy improvements | MRE11, TP53, CHEK2 | CYP3A4 3423/4885MAOA 4377/4885MAOB 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.